Criterion Capital Advisors LLC Increases Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Criterion Capital Advisors LLC increased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 38.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,184 shares of the medical research company’s stock after buying an additional 330 shares during the period. Criterion Capital Advisors LLC’s holdings in Thermo Fisher Scientific were worth $688,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norges Bank bought a new stake in Thermo Fisher Scientific in the fourth quarter worth $2,909,524,000. International Assets Investment Management LLC increased its holdings in shares of Thermo Fisher Scientific by 61,995.4% in the 4th quarter. International Assets Investment Management LLC now owns 1,009,671 shares of the medical research company’s stock worth $535,923,000 after buying an additional 1,008,045 shares during the last quarter. Veritas Asset Management LLP raised its position in shares of Thermo Fisher Scientific by 70.1% during the 4th quarter. Veritas Asset Management LLP now owns 1,692,148 shares of the medical research company’s stock valued at $898,175,000 after buying an additional 697,383 shares in the last quarter. Winslow Capital Management LLC purchased a new position in Thermo Fisher Scientific in the fourth quarter worth about $333,786,000. Finally, Clearbridge Investments LLC raised its position in Thermo Fisher Scientific by 33.1% during the fourth quarter. Clearbridge Investments LLC now owns 2,228,730 shares of the medical research company’s stock valued at $1,182,987,000 after purchasing an additional 553,695 shares during the period. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Stock Up 0.4 %

Shares of NYSE TMO traded up $2.22 during midday trading on Friday, reaching $553.00. 6,150,885 shares of the company’s stock traded hands, compared to its average volume of 1,473,906. The company has a market cap of $211.09 billion, a price-to-earnings ratio of 35.45, a P/E/G ratio of 2.57 and a beta of 0.79. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82. The company has a quick ratio of 1.33, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. The stock’s 50 day simple moving average is $574.84 and its 200-day simple moving average is $562.59.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. The business had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. On average, analysts predict that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Friday, June 14th will be given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.28%. The ex-dividend date of this dividend is Friday, June 14th. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

Analysts Set New Price Targets

TMO has been the topic of several analyst reports. Barclays cut their target price on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a research report on Friday. Jefferies Financial Group restated a “buy” rating and issued a $650.00 target price (up previously from $600.00) on shares of Thermo Fisher Scientific in a report on Monday, June 3rd. Deutsche Bank Aktiengesellschaft upped their price target on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a report on Thursday, April 25th. The Goldman Sachs Group boosted their target price on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Finally, Citigroup initiated coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They issued a “neutral” rating and a $620.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average price target of $607.06.

Insider Buying and Selling

In other news, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction on Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the sale, the senior vice president now owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the sale, the senior vice president now directly owns 13,083 shares in the company, valued at approximately $7,430,359.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at approximately $70,873,516.56. The disclosure for this sale can be found here. Insiders sold a total of 22,000 shares of company stock worth $12,532,780 in the last 90 days. 0.34% of the stock is owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.